MA31766B1 - Composés organiques - Google Patents
Composés organiquesInfo
- Publication number
- MA31766B1 MA31766B1 MA32756A MA32756A MA31766B1 MA 31766 B1 MA31766 B1 MA 31766B1 MA 32756 A MA32756 A MA 32756A MA 32756 A MA32756 A MA 32756A MA 31766 B1 MA31766 B1 MA 31766B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- organic compounds
- alk
- relates
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
La présente invention concerne des composés de formule (i) : sous une forme libre ou de sel ou de solvate, dans laquelle r1, r2, r3 et r20 ont les significations indiquées dans la spécification, qui sont utiles pour traiter des maladies induites par le récepteur alk-5 et/ou alk-4. L'invention concerne également des compositions pharmaceutiques qui contiennent les composés et des procédés de préparation des composés.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07118726 | 2007-10-17 | ||
EP08151336 | 2008-02-12 | ||
PCT/EP2008/063841 WO2009050183A2 (fr) | 2007-10-17 | 2008-10-15 | Composés organiques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31766B1 true MA31766B1 (fr) | 2010-10-01 |
Family
ID=39944334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32756A MA31766B1 (fr) | 2007-10-17 | 2010-04-08 | Composés organiques |
Country Status (23)
Country | Link |
---|---|
US (1) | US8367662B2 (fr) |
EP (1) | EP2212323B1 (fr) |
JP (1) | JP5456681B2 (fr) |
KR (1) | KR20100076022A (fr) |
CN (1) | CN101827844B (fr) |
AR (1) | AR068877A1 (fr) |
AU (1) | AU2008313773B2 (fr) |
BR (1) | BRPI0817434A2 (fr) |
CA (1) | CA2703037A1 (fr) |
CL (1) | CL2008003056A1 (fr) |
CO (1) | CO6270321A2 (fr) |
EA (1) | EA201000615A1 (fr) |
ES (1) | ES2393430T3 (fr) |
IL (1) | IL204720A0 (fr) |
MA (1) | MA31766B1 (fr) |
MX (1) | MX2010004244A (fr) |
PE (1) | PE20091383A1 (fr) |
PL (1) | PL2212323T3 (fr) |
PT (1) | PT2212323E (fr) |
TN (1) | TN2010000167A1 (fr) |
TW (1) | TW200922570A (fr) |
WO (1) | WO2009050183A2 (fr) |
ZA (1) | ZA201002334B (fr) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8343966B2 (en) * | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
FR2945806B1 (fr) * | 2009-05-19 | 2013-04-05 | Sanofi Aventis | Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met |
JP2011528338A (ja) * | 2008-07-18 | 2011-11-17 | サノフイ−アベンテイス | 新規イミダゾ[1,2−a]ピリジン誘導体、この調製方法、この医薬としての使用、医薬組成物、および新規用途、特にMET阻害剤としての用途 |
MX2011012037A (es) * | 2009-05-13 | 2012-02-28 | Amgen Inc | Compuestos de heteroarilo como inhibidores de pikk. |
CN102471345A (zh) * | 2009-07-15 | 2012-05-23 | 雅培制药有限公司 | 激酶的吡咯并吡嗪抑制剂 |
UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
WO2011146287A1 (fr) | 2010-05-20 | 2011-11-24 | Takeda Pharmaceutical Company Limited | Inhibiteurs d'alk 5 à base de pyrazolo[4,3-b]pyridine-7-amine |
CN102443009B (zh) * | 2010-09-30 | 2014-04-16 | 山东轩竹医药科技有限公司 | 并环激酶抑制剂 |
EP2463289A1 (fr) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Dérivés imidazo[1,2-b]pyridazine en tant qu'inhibiteur JAK |
AU2012280508A1 (en) * | 2011-07-01 | 2013-12-12 | Bayer Intellectual Property Gmbh | Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors |
EP2554544A1 (fr) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Dérivés de pyridin-2(1h)-one en tant qu'inhibiteurs de JAK |
ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
PT3738434T (pt) * | 2011-12-28 | 2023-11-13 | Global Blood Therapeutics Inc | Intermediários para obter compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos |
GB201205669D0 (en) * | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
PT3176170T (pt) | 2012-06-13 | 2019-02-05 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
US9738636B2 (en) | 2012-09-28 | 2017-08-22 | Vanderbilt University | Fused heterocyclic compounds as selective BMP inhibitors |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
PE20160078A1 (es) | 2013-03-15 | 2016-03-02 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EA033555B1 (ru) | 2013-03-15 | 2019-10-31 | Global Blood Therapeutics Inc | Фармацевтические композиции для лечения серповидно-клеточного нарушения |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
PE20152033A1 (es) | 2013-04-19 | 2016-01-21 | Incyte Holdings Corp | Heterociclos bicicliclos como inhibidores de fgfr |
WO2015031285A1 (fr) * | 2013-08-27 | 2015-03-05 | Global Blood Therapeutics, Inc. | Sels d'ansolvats 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde cristallins |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
MY189995A (en) | 2014-02-07 | 2022-03-22 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
US10501438B2 (en) | 2015-08-11 | 2019-12-10 | Neomed Institute | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals |
US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
ES2904258T3 (es) | 2015-08-12 | 2022-04-04 | Neomed Inst | Bencimidazoles sustituidos, su preparación y su uso como productos farmacéuticos |
WO2017066876A1 (fr) | 2015-10-21 | 2017-04-27 | Neomed Institute | Imidazopyridines substituées, leur préparation et leur utilisation comme médicaments |
US11020382B2 (en) | 2015-12-04 | 2021-06-01 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
WO2017127930A1 (fr) | 2016-01-28 | 2017-08-03 | Neomed Institute | [1,2,4]triazolo[4,3-a]pyridines substituées, leur préparation et leur utilisation comme médicaments |
AR108435A1 (es) | 2016-05-12 | 2018-08-22 | Global Blood Therapeutics Inc | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído |
US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
EP3512834A4 (fr) * | 2016-09-14 | 2020-05-06 | Vanderbilt University | Inhibition de la signalisation bmp, composés, compositions et leurs utilisations |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
KR20200115620A (ko) | 2018-01-29 | 2020-10-07 | 메르크 파텐트 게엠베하 | Gcn2 억제제 및 이의 용도 |
WO2019178383A1 (fr) | 2018-03-14 | 2019-09-19 | Vanderbilt University | Inhibition de la signalisation bmp, composés, compositions et leurs utilisations |
CN112867716A (zh) | 2018-05-04 | 2021-05-28 | 因赛特公司 | Fgfr抑制剂的固体形式和其制备方法 |
CA3099116A1 (fr) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Sels d'un inhibiteur de fgfr |
ES2966707T3 (es) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Moduladores de la hemoglobina para el tratamiento de la drepanocitosis |
AU2019401649A1 (en) | 2018-12-20 | 2021-07-08 | Incyte Corporation | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
WO2020185532A1 (fr) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr |
WO2021007269A1 (fr) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
CN114072402B (zh) * | 2019-07-26 | 2023-12-26 | 盛世泰科生物医药技术(苏州)股份有限公司 | 作为fgfr和vegfr双重抑制剂的吡啶衍生物 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3162010A1 (fr) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derives d'un inhibiteur de fgfr |
CA3163875A1 (fr) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Heterocycles tricycliques en tant qu'inhibiteurs de fgfr |
CN111116582B (zh) * | 2019-12-18 | 2022-07-29 | 大连大学 | 一种mGluR2拮抗剂 |
CA3157396A1 (fr) * | 2019-12-19 | 2021-06-24 | Universite De Strasbourg | Ligands du recepteur sigma-1 et ses utilisations therapeutiques |
US20230090552A1 (en) | 2020-01-08 | 2023-03-23 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
US20210214366A1 (en) * | 2020-01-15 | 2021-07-15 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
CN114728965A (zh) * | 2020-01-21 | 2022-07-08 | 四川科伦博泰生物医药股份有限公司 | 吡啶并杂环类化合物、其制备方法及用途 |
AU2021288107A1 (en) | 2020-06-12 | 2022-12-15 | Incyte Corporation | Imidazopyridazine compounds with activity as ALK2 inhibitors |
JP2023533850A (ja) | 2020-07-15 | 2023-08-04 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Alk5阻害剤としてのピリドオキサジンアミノ誘導体 |
US20240116947A1 (en) | 2020-07-15 | 2024-04-11 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
BR112023000588A8 (pt) | 2020-07-15 | 2023-05-09 | Chiesi Farm Spa | Derivados de piridazinil amino como inibidores de alk5 |
US20240116948A1 (en) | 2020-12-23 | 2024-04-11 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
JP2024504437A (ja) * | 2021-01-26 | 2024-01-31 | シージーンテック (スーチョウ, チャイナ) カンパニー リミテッド | メチルピラゾール置換ピリドイミダゾール系化合物の結晶及びその製造方法 |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
TW202328102A (zh) | 2021-09-21 | 2023-07-16 | 義大利商吉斯藥品公司 | 作為alk5抑制劑之嗒𠯤基胺基衍生物 |
WO2023057389A1 (fr) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | Composés inhibiteurs de parg |
WO2023208986A1 (fr) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Dérivés d'imidazole en tant qu'inhibiteurs d'alk5 |
WO2024074497A1 (fr) | 2022-10-03 | 2024-04-11 | Forx Therapeutics Ag | Composé inhibiteur de parg |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1016489B (it) | 1974-03-18 | 1977-05-30 | Isf Spa | Inalatore |
DK0865302T3 (da) | 1995-12-07 | 2000-10-02 | Jago Pharma Ag | Inhalator til gentagen dosisvis afgivelse af farmakologisk tørpulver |
JP3830972B2 (ja) | 1996-02-21 | 2006-10-11 | シェーリング コーポレイション | 粉体薬剤吸入器 |
GB9927687D0 (en) * | 1999-11-23 | 2000-01-19 | Merck Sharp & Dohme | Therapeutic agents |
DE10117183A1 (de) * | 2001-04-05 | 2002-10-10 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel |
ES2310202T3 (es) * | 2001-04-26 | 2009-01-01 | EISAI R&D MANAGEMENT CO., LTD. | Compuesto ciclico condensado que contiene nitrogeno que tiene un grupo pirazolilo como grupo sustituyente y composicion farmaceutica del mismo. |
GB0128499D0 (en) | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
CA2483084A1 (fr) * | 2002-05-02 | 2003-11-13 | Merck & Co., Inc. | Inhibiteurs de la tyrosine kinase |
WO2004013135A1 (fr) * | 2002-07-31 | 2004-02-12 | Smithkline Beecham Corporation | Derives de c2-phenylpyridine-4-yl en tant qu'inhibiteurs d'alk5 |
GB0217783D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
GB2407042B (en) | 2003-10-17 | 2007-10-24 | Vectura Ltd | Inhaler |
GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
JP4972804B2 (ja) * | 2004-08-31 | 2012-07-11 | Msd株式会社 | 新規置換イミダゾール誘導体 |
JP2008516962A (ja) * | 2004-10-15 | 2008-05-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 血管傷害を治療する方法 |
DOP2006000051A (es) * | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
US8895745B2 (en) * | 2006-12-22 | 2014-11-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
-
2008
- 2008-10-15 CA CA2703037A patent/CA2703037A1/fr not_active Abandoned
- 2008-10-15 EA EA201000615A patent/EA201000615A1/ru unknown
- 2008-10-15 ES ES08838625T patent/ES2393430T3/es active Active
- 2008-10-15 KR KR1020107010615A patent/KR20100076022A/ko not_active Application Discontinuation
- 2008-10-15 US US12/679,549 patent/US8367662B2/en not_active Expired - Fee Related
- 2008-10-15 PE PE2008001769A patent/PE20091383A1/es not_active Application Discontinuation
- 2008-10-15 CN CN2008801122032A patent/CN101827844B/zh not_active Expired - Fee Related
- 2008-10-15 PL PL08838625T patent/PL2212323T3/pl unknown
- 2008-10-15 BR BRPI0817434-2A patent/BRPI0817434A2/pt not_active IP Right Cessation
- 2008-10-15 AU AU2008313773A patent/AU2008313773B2/en not_active Ceased
- 2008-10-15 PT PT08838625T patent/PT2212323E/pt unknown
- 2008-10-15 MX MX2010004244A patent/MX2010004244A/es active IP Right Grant
- 2008-10-15 JP JP2010529359A patent/JP5456681B2/ja not_active Expired - Fee Related
- 2008-10-15 WO PCT/EP2008/063841 patent/WO2009050183A2/fr active Application Filing
- 2008-10-15 AR ARP080104492A patent/AR068877A1/es unknown
- 2008-10-15 EP EP08838625A patent/EP2212323B1/fr active Active
- 2008-10-16 TW TW097139735A patent/TW200922570A/zh unknown
- 2008-10-16 CL CL2008003056A patent/CL2008003056A1/es unknown
-
2010
- 2010-03-25 IL IL204720A patent/IL204720A0/en unknown
- 2010-04-01 ZA ZA2010/02334A patent/ZA201002334B/en unknown
- 2010-04-08 MA MA32756A patent/MA31766B1/fr unknown
- 2010-04-16 TN TN2010000167A patent/TN2010000167A1/fr unknown
- 2010-05-11 CO CO10056124A patent/CO6270321A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PT2212323E (pt) | 2012-11-27 |
KR20100076022A (ko) | 2010-07-05 |
ZA201002334B (en) | 2011-03-30 |
TN2010000167A1 (en) | 2011-11-11 |
JP5456681B2 (ja) | 2014-04-02 |
PL2212323T3 (pl) | 2013-01-31 |
ES2393430T3 (es) | 2012-12-21 |
EP2212323A2 (fr) | 2010-08-04 |
CN101827844A (zh) | 2010-09-08 |
IL204720A0 (en) | 2010-11-30 |
US8367662B2 (en) | 2013-02-05 |
CA2703037A1 (fr) | 2009-04-23 |
EP2212323B1 (fr) | 2012-08-15 |
CL2008003056A1 (es) | 2009-07-31 |
TW200922570A (en) | 2009-06-01 |
JP2011500623A (ja) | 2011-01-06 |
AU2008313773A8 (en) | 2010-04-29 |
MX2010004244A (es) | 2010-04-30 |
WO2009050183A3 (fr) | 2009-07-16 |
AU2008313773A1 (en) | 2009-04-23 |
US20100210641A1 (en) | 2010-08-19 |
WO2009050183A2 (fr) | 2009-04-23 |
PE20091383A1 (es) | 2009-10-17 |
AR068877A1 (es) | 2009-12-09 |
BRPI0817434A2 (pt) | 2015-06-16 |
CO6270321A2 (es) | 2011-04-20 |
AU2008313773B2 (en) | 2012-04-12 |
CN101827844B (zh) | 2013-08-14 |
EA201000615A1 (ru) | 2010-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31766B1 (fr) | Composés organiques | |
MA31952B1 (fr) | Pyrrolopyrimidines et pyrrolopyridines | |
MA27775A1 (fr) | Composes organiques | |
TNSN07022A1 (fr) | Derives de pyridine | |
MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
TNSN07275A1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
TN2009000450A1 (fr) | Derives de pyridine | |
MA29926B1 (fr) | Derives de pyrazine | |
MA33450B1 (fr) | Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques | |
TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
MA31894B1 (fr) | Composes organiques | |
MA31521B1 (fr) | Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central | |
EP1725536B8 (fr) | Derives de l'imidazoline presentant une activite antagoniste cb1 | |
TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
MA31683B1 (fr) | Composes et procedes pour moduler fxr | |
MA31754B1 (fr) | Cis-imidazolines chirales | |
TW200612936A (en) | Indole derivatives | |
MX2008002061A (es) | Derivados de tiazolil piperidina utiles como moduladores del receptor h3. | |
MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
UA83862C2 (ru) | Производные тиазола как модуляторы рецепторов канабиноидов | |
EP1689713A4 (fr) | Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer | |
EP2091328A4 (fr) | Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer | |
MXPA05010824A (es) | Compuestos biciclicos como antagonistas del receptor nr2b. |